Trial
NCT03026803
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
City of Hope Medical Center
Collaborators
Sanofi
Condition
Liver Cancer
Intervention
Oxaliplatin
Why stopped
Due to Sorafenib became first line treatment for HCC, the designed treatment became less competitive. The company Sanofi decided not to continue to support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-04-13